[go: up one dir, main page]

KR900003136A - 6-플루오로-3, 5- 디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 이의 약제로서의 용도, 약학적 생성물 및 중간체 - Google Patents

6-플루오로-3, 5- 디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 이의 약제로서의 용도, 약학적 생성물 및 중간체 Download PDF

Info

Publication number
KR900003136A
KR900003136A KR1019890011243A KR890011243A KR900003136A KR 900003136 A KR900003136 A KR 900003136A KR 1019890011243 A KR1019890011243 A KR 1019890011243A KR 890011243 A KR890011243 A KR 890011243A KR 900003136 A KR900003136 A KR 900003136A
Authority
KR
South Korea
Prior art keywords
alkyl
carbon atoms
formula
compound
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019890011243A
Other languages
English (en)
Inventor
하르트 벡크 게르
바르트만 빌헬름
베스 귄터
그란쩌 에르놀트
Original Assignee
하인리히 벡커, 베른 하르트 벡크
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커, 베른 하르트 벡크, 훽스트 아크티엔게젤샤프트 filed Critical 하인리히 벡커, 베른 하르트 벡크
Publication of KR900003136A publication Critical patent/KR900003136A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C07C33/48—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts with unsaturation outside the aromatic rings
    • C07C33/486—Polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/55—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/48—Aldehydo radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

6-플루오로-3,5-디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 이의 약제로서의 용도, 약학적 생성물 및 중간체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 일반식(I)의 6-플루오로-3,5-디하이드록시 카복실산 및 이의 유도체 및 상응하는 일반식(Ⅱ)의 락톤.
    상기식에서, R1은 A) 치환된 6-원 환 방향족 및 헤테로 방향족 a,b,c 그룹
    [여기서, Z는 구조식 -CH의 라디칼 또는 질소 원자를 나타내고, R3, R4및 R5는 서로 독립적으로 수소, 각각 탄소수 3내지 6의 사이클로알킬 또는 사이클로알케닐 라디칼에 의해 말단 탄소에서 임의로 치환될 수 있는, 각각의 탄소수가 6 이하인 직쇄 또는 측쇄 알킬 또는 알케닐 라디칼을 나타내거나, 포화되거나 이중으로 불포환된 3 내지 7의 사이클릭 탄화수소라디칼, 또는 핵에서 각각의 탄소수가 6이하인 알킬 또는 알케닐, 하이드록실, 탄소수 1 내지 6의 알콕시, 알콕시 잔기의 탄소수가 1 내지 6인 카복실 또는 카브알콕시 그룹으로부터 1 내지 3개의 같거나 다른 치환기를 임의로 함유할 수 있는, 페닐, 푸릴, 티에닐 및 피리디닐 중에서 선택된 방향족 라디칼을 나타낸다], B) 치환된 5-원 또는 헤테로 방향족 그룹
    [여기서, G-E는 방향족 순열 a) N-C(1H-피롤-2-일) b) S-C(2-티에닐) c) C-N(1H-피롤-3-일) d) C-O(3-푸릴) e) C-S(3-티에닐)을 나타내고, R6는 H, 직쇄 C1-C4-알킬, C3-C6-측쇄 알킬, 트리플루오로메틸, 할로겐, 또는 불소, 염소, 또는 메틸에 의해 임의로 1 내지 2회 치환되는 페닐을 나타내며, R7은 H, 직쇄 C1-C4-알킬, 측쇄 C3-C6-알킬, 트리플루오로메틸, 할로겐 또는 페닐을 나타내고, R8은 H, 환 탄소수 5 내지 8의 사이클로알킬, 측쇄 C3-C6-알킬, 또는 직쇄 C1-C3-알킬, 할로겐 또는 트리플루오로메틸에 의해 임의로 1 내지 2회 치환될 수 있는 페닐을 나타내며, R9은 H, 직쇄 C1-C3-알킬, 측쇄 C3-C6-알킬, 환탄소수 5 내지 8의 사이클로알킬, 트리플루오로메틸, 또는 직쇄 C1-C3-알킬, 할로겐 또는 트리플루오로메틸에 의해 임의로 1 내지 2회 치환될 수 있는 페닐을 나타내고, R7및 R9은 함께 또한 탄소수 4의 공액(conjugated) 불포화 라디칼을 나타내어 이들이 융합-방향족 잔기를 형성하며, 치환기 R7및 R8은 적절한 위치에서 산소 및 황을 지닌 헤테로 방향족에서 존재하지 않는다], 또는 c) 치환된-올레핀 그룹
    [여기서, R10, R11및 R12는 서로 독립적으로 각각 탄소수 3 내지 6의 사이클로알킬 또는 사이클로알케닐 라디칼에 의해 말단 탄소에서 임의로 치환될 수 있는, 각각의 탄소수가 6 이하인 직쇄 또는 측쇄 알킬 또는 알케닐 라디칼을 나타내거나, 포화되거나 이중으로 불포화된 탄소수 3 내지 7의 사이클릭 탄화수소 라디칼, 또는 핵에서 각각의 탄소수가 6 이하인 알킬 또는 알케닐, 하이드록실, 탄소수 1 내지 6의 알콕시, 알콕시 잔기의 탄소수가 1 내지 6인 카복실 또는 카브알콕시 그룹으로부터 1 내지 3개의 같거나 다른 치환기를 임의로 함유할 수 있는, 페닐, 푸릴, 티에닐 또는 피리디닐 중에서 선택된 방향족 라디칼을 나타낸다]이고, R2는 수소, 각각의 탄소수가 8 이하인 직쇄 또는 측쇄 알킬 또는 알케닐 라디칼, 핵이 할로겐 또는 탄소수 1 내지 4인 알킬 라디칼로 1 내지 2회 치환될 수 있는 벤질라디칼을 나타내거나, 알카리 금속 또는 암모늄 이온 NR13, R14, R15, R16(여기서, R13, R14, R15, 및 R16은 같거나 다르며 수소, 탄소수 1 내지 4의 알킬 또는 탄소수 1 내지 4의 하이드록시 알킬을 나타낸다)을 나타낸다.
  2. a) 적절하게 치환된 일반식(Ⅲ)의 알데히드를 상응하는 일반식(Ⅳ)의 하이드록시에스테르로 전환시키고, b) 비키랄성 아세트산에스테르 에놀레이트를 지닌 광학 활성 일반식(Ⅳ)의 화합물을, 즉시 또는 미리 상응하는 알킬 에스테르로 전환시킨 후, 광학 활성 일반식(Ⅴ)의 화합물을 전환시키며, c) 일반식(Ⅴ)의 하이드록시케토 에스테르를 상응하는 일반식(Ⅰ)의 6-플루오로-3,5-디하이드록시 화합물로 전환시키고, 경우에 따라, 수득한 화합물을 R2가 금속양이온인 일반식(Ⅰ)의 화합물로 가수분해시키고, 경우에 따라 이로부터 유리산(R2=수소)을 유리시키며, 경우에 따라 유리산을 R2가 각각의 탄소수가 8 이하인 알킬 또는 알케닐, 암모늄 이온, 벤질 또는 적절하게 치환된 벤질인 일반식(Ⅰ)의 화합물로 전환시키며, d) 수득한 일반식(Ⅰ)의 화합물을 경우에 따라 일반식(Ⅱ)의 락톤으로 전환시킴을 특징으로 하여, 일반식(Ⅰ) 및 (Ⅱ)의 화합물을 제조하는 방법.
    상기식에서, R1은 제1항에서 정의한 바와 같고, R17은 C-3에서 입체 화학을 결정하는 적합한 광학 활성산 보호 그룹, 또는 탄소수 1 내지 8의 알킬 라디칼을 나타내고, R18은 탄소수 1 내지 8의 알킬을 나타내며, R2는 탄소수 1 내지 8의 알킬이다.
  3. 제1항에 청구한 화합물을 함유하는 약학적 생성물.
  4. 동맥 경화증 및 콜레스테롤 과다증의 예방 및 치료를 위한, 제1항에 청구한 화합물의 용도.
  5. 일반식(Ⅲ)의 화합물.
    상기식에서, R1은 제1항의 일반식(Ⅰ)에서 정의한 바와 같다.
  6. 일반식(Ⅳ)의 화합물.
    상기식에서, R1은 제1항의 일반식(Ⅰ)에서 정의한 바와 같고, R17은 탄소수 1 내지 8의 알킬이다.
  7. 일반식(Ⅴ)의 화합물.
    상기식에서, R1은 제1항의 일반식(Ⅰ)에서 정의한 바와 같고, R18은 탄소수 1 내지 8의 알킬이다.
  8. 일반식(Ⅵ)의 화합물.
    상기식에서, R1은 일반식(Ⅰ)에 대해 상기 정의한 바와 같고, X는 니트릴 그룹(C=N) 또는 에스테르 그룹 COOR19(여기서, R19는 탄소수 1 내지 8의 알킬이다)이다.
  9. 일반식(Ⅶ)의 화합물.
    상기식에서, R1은 제1항에서 일반식(Ⅰ)에 대해 정의한 바와 같다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890011243A 1988-08-06 1989-08-05 6-플루오로-3, 5- 디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 이의 약제로서의 용도, 약학적 생성물 및 중간체 Ceased KR900003136A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP3826814.0 1988-08-06
DE3826814A DE3826814A1 (de) 1988-08-06 1988-08-06 Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte

Publications (1)

Publication Number Publication Date
KR900003136A true KR900003136A (ko) 1990-03-23

Family

ID=6360401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890011243A Ceased KR900003136A (ko) 1988-08-06 1989-08-05 6-플루오로-3, 5- 디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 이의 약제로서의 용도, 약학적 생성물 및 중간체

Country Status (16)

Country Link
US (1) US5204351A (ko)
EP (1) EP0354418B1 (ko)
JP (1) JPH0291034A (ko)
KR (1) KR900003136A (ko)
AT (1) ATE105838T1 (ko)
AU (1) AU616291B2 (ko)
DE (2) DE3826814A1 (ko)
DK (1) DK384489A (ko)
ES (1) ES2054947T3 (ko)
FI (1) FI90546C (ko)
IE (1) IE63491B1 (ko)
IL (1) IL91212A (ko)
NO (1) NO175637C (ko)
NZ (1) NZ230217A (ko)
PT (1) PT91362B (ko)
ZA (1) ZA895959B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100427397B1 (ko) * 2001-02-27 2004-04-27 세신전자(주) 질소산화물 환원용 촉매의 제조방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3722809A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 3-desmethyl-4-fluor-mevalonsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen, ihre verwendung und zwischenprodukte
DE3800785A1 (de) * 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
AU7891891A (en) * 1990-05-25 1991-12-31 Fujisawa Pharmaceutical Co., Ltd. Pyrrolopyridazine compounds
EP0469480A3 (en) * 1990-08-01 1993-03-10 Hoechst Aktiengesellschaft Process for stereoselective preparation of 5-substituted delta-lactones and their use
US5292898A (en) * 1990-08-01 1994-03-08 Hoechst Aktiengesellschaft Process for the stereoselective preparation of 5-substituted delta-lactones and use thereof
JP2001335476A (ja) * 2000-05-29 2001-12-04 Shionogi & Co Ltd 三環化合物の新規用途
US20040235877A1 (en) * 2001-09-14 2004-11-25 Natsuki Ishizuka Novel use of tricyclic compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221025A1 (en) * 1985-10-25 1987-05-06 Sandoz Ag Heterocyclic analogs of mevalonolactone and derivatives thereof, processes for their production and their use as pharmaceuticals
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
DE3722807A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag Neue 3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3722809A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 3-desmethyl-4-fluor-mevalonsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen, ihre verwendung und zwischenprodukte
FI90236C (fi) * 1987-07-10 1994-01-10 Hoechst Ag Menetelmä terapeuttisesti käyttökelpoisten 3-desmetyylimevalonihappojohdannaisten valmistamiseksi
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US4906624A (en) * 1987-09-08 1990-03-06 Warner-Lambert Company 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3800785A1 (de) * 1988-01-09 1989-07-20 Hoechst Ag Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
NO890521L (no) * 1988-02-25 1989-08-28 Bayer Ag Substituerte pyrimidiner.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100427397B1 (ko) * 2001-02-27 2004-04-27 세신전자(주) 질소산화물 환원용 촉매의 제조방법

Also Published As

Publication number Publication date
FI893677A0 (fi) 1989-08-03
DK384489D0 (da) 1989-08-04
ZA895959B (en) 1990-04-25
IE63491B1 (en) 1995-05-03
FI893677L (fi) 1990-02-07
IL91212A0 (en) 1990-03-19
US5204351A (en) 1993-04-20
ES2054947T3 (es) 1994-08-16
DE3826814A1 (de) 1990-02-08
DK384489A (da) 1990-02-07
AU616291B2 (en) 1991-10-24
EP0354418B1 (de) 1994-05-18
FI90546C (fi) 1994-02-25
DE58907678D1 (de) 1994-06-23
IL91212A (en) 1994-01-25
NO893167D0 (no) 1989-08-04
AU3929789A (en) 1990-02-08
PT91362A (pt) 1990-03-08
NZ230217A (en) 1991-12-23
NO175637B (ko) 1994-08-01
NO175637C (no) 1994-11-09
NO893167L (no) 1990-02-07
EP0354418A3 (de) 1991-07-31
EP0354418A2 (de) 1990-02-14
IE892539L (en) 1990-02-06
FI90546B (fi) 1993-11-15
PT91362B (pt) 1995-03-31
JPH0291034A (ja) 1990-03-30
ATE105838T1 (de) 1994-06-15

Similar Documents

Publication Publication Date Title
KR890002119A (ko) 3-데메틸메발론산 유도체, 이의 제조방법, 이 화합물을 기본으로 하는 약제학적 조성물, 이의 용도 및 중간체
KR830006219A (ko) 아미노산 유도체의 제조방법
HUT59676A (en) Process for producing piperazinyl-alkyl-carbonyl derivatives of condensed heterocyclic compounds and pharmaceutical compositions containing them
KR830009118A (ko) 세펨화합물의 제조방법
KR900003136A (ko) 6-플루오로-3, 5- 디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 이의 약제로서의 용도, 약학적 생성물 및 중간체
KR890011859A (ko) 3,5-디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 약물로서의 이의 용도, 약제학적 생성물 및 중간체
KR840003628A (ko) 피리딜화합물의 제조방법
KR840004079A (ko) 피리딘카복실산 에스테르의 제조방법
US3882110A (en) Novel 2-alkyl-5-thiazole-carboxylic acid derivatives
KR890002084A (ko) 3-데메틸-4-플루오로메발론산 유도체, 이의 제조방법, 이들 화합물을 기초로하는 약제학적 생성물, 이들 용도 및, 중간체
IE800688L (en) Xanthine derivatives
AU585987B2 (en) Process for the preparation of 2-arylpropionic acids
KR870001212A (ko) 피리딘 유도체의 제조방법
IE38821B1 (en) Thiophene derivatives process for their preparation and compositions incorporating them
AU8148087A (en) Process for the preparation of 2-arylpropionic acids
KR890001941A (ko) 3,5-디하이드록시카복실산 및 이의 유도체, 이의 제조방법, 약제로서의 이의 용도, 약제학적 조성물 및 중간생성물
KR890012990A (ko) 삼치환된 아민 이들의 제법 및 이들을 함유하는 제약조성물
IE39576B1 (en) Derivatives of 3-(p-chlorobenzoyl)-2-methyl-phenylacetic acid
KR890002174A (ko) 삼환성 세팜 화합물, 그의 제조방법 및 용도
DE3362846D1 (en) Derivatives of benzo-1,2-thiazine-1,1-dioxide, a process for their preparation and pharmaceutical compositions containing the same
KR840002855A (ko) Omt에스테르 유도체의 제조방법
IE39770B1 (en) Thiazole derivatives
KR890008145A (ko) 비페닐 유도체 및 이의 제조방법
KR910011867A (ko) 세팔로스포린 유도체와 이의 제조방법
KR890006651A (ko) 리파마이신 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890805

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940614

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19890805

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970213

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19970430

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19970213

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I